2024年ASCO年会HR+/HER2-晚期乳腺癌治疗研究进展

Research progress on the treatment of HR+/HER2-metastatic breast cancer at 2024 American Society of Clinical Oncology annual meeting

摘要: 2024年美国临床肿瘤学会（American Society of Clinical Oncology，ASCO）年会的主题为“癌症诊疗的科学与艺术：从关怀到治愈（The art and science of cancer care: from comfort to cure）”。在晚期乳腺癌领域，激素受体（hormonal receptor，HR）阳性/人类表皮生长因子受体-2（human epidermal growth factor receptor 2，HER2）阴性亚型的相关研究占据大量篇幅，其中3篇压轴公布的重要研究（late-breaking abstract，LBA）分别报道了post MONARCH研究（LBA1001）、Young-PEARL研究（LBA1002）、SACI-IO HR+研究（LBA1004）的最新结果，引起广泛关注。本文就本次年会中关于HR+/HER2-晚期乳腺癌治疗的研究进展进行综合报道。

Abstract: The theme of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting is "The art and science of cancer care: from comfort to cure." Extensive research was presented on the hormonal receptor (HR)-positive/ human epidermal growth factor receptor 2 (HER2)-negative subtype of metastatic breast cancer. Three late-breaking abstracts (LBA) reported the latest findings of the post MONARCH (LBA1001), Young-PEARL (LBA1002), and SACI-IO HR+ (LBA1004) studies , generating significant interest. In this paper, we present a comprehensive review of the progress on HR+/HER2- metastatic breast cancer treatment research as reported at this annual meeting.